Coronavirus (COVID-19): Important Information From Scripps Learn more
Short duration infusion for treatment of Follicular Lymphoma
In response to the COVID pandemic, Scripps Health has temporarily suspended enrollment for all clinical trials. Exceptions will exist for trials with curative intent, life-saving treatment or when no standard of care exists. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.
James Mason, M.D.
The purpose of this study is to test the safety and effectiveness of a short duration infusion (90 minute infusion) of obinutuzumab in patients who have previously untreated advanced follicular lymphoma. Patients in this study will receive obinutizumab along with chemotherapy.
Be 18 years of age or older
Have previously untreated Stage III or IV follicular lymphoma or Stage II bulky disease
Have histologically documented CD-20-positive follicular lymphoma
Have relapsed / refractory or Grade IIIb follicular lymphoma
Have had prior treatment for follicular lymphoma with chemotherapy, radiotherapy, or immunotherapy
Have a history of anti-CD20 antibody therapy
Be pregnant, breastfeeding or planning on becoming pregnant
All treatments and physician visits will take place at Scripps Clinic Torrey Pines.
Study participation is expected to last up to 2.75 years